BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of crotalid snake envenomations; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup; and Lemtrada. The company also manufactures and commercializes therapeutic ultrasound devices, and roxwood systems, as well as develops venous thrombus management devices. The company was formerly known as British Technology Group International plc and changed its name to BTG plc in March 1995. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
CIKN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees1,631
Next Earnings DateN/A
OptionableNot Optionable
BTG (OTCMKTS:BTGGF) Frequently Asked Questions
What is BTG's stock symbol?
BTG trades on the OTCMKTS under the ticker symbol "BTGGF."
What is the consensus analysts' recommendation for BTG?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BTG in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for BTG.
Has BTG been receiving favorable news coverage?
Headlines about BTGGF stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. BTG earned a news sentiment score of 0.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an effect on the stock's share price in the next several days.
Who are some of BTG's key competitors?
Some companies that are related to BTG include EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), PRA Health Sciences (PRAH), Syneos Health (SYNH), Medpace (MEDP), Intrexon (XON), Geovax Labs (GOVX), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Pieris Pharmaceuticals (PIRS) and Luna Innovations (LUNA).
What other stocks do shareholders of BTG own?
Who are BTG's key executives?
BTG's management team includes the folowing people:
- Dr. Louise Makin MA, Ph.D.(Cantab), MBA, DBE, CEO & Exec. Director (Age 58)
- Mr. Duncan Kennedy A.C.A., B.Sc., CFO & Director
- Dr. Peter Stratford, Chief Technical Officer & Head of Innovation (Age 52)
- Mr. Andy Burrows, VP of Corp. & Investor Relations
- Dr. Paul Mussenden, Gen. Counsel, Head of Strategic Affairs & Company Sec.
How do I buy shares of BTG?
Shares of BTGGF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BTG's stock price today?
One share of BTGGF stock can currently be purchased for approximately $10.56.
How big of a company is BTG?
BTG has a market capitalization of $4.08 billion. BTG employs 1,631 workers across the globe.
MarketBeat Community Rating for BTG (OTCMKTS BTGGF)
MarketBeat's community ratings are surveys of what our community members think about BTG and other stocks. Vote "Outperform" if you believe BTGGF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTGGF will underperform the S&P 500 over the long term. You may vote once every thirty days.
